Clinical Trial Update: A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) [Phase 2]

View source ↗

Summary

A Phase 2 study of pembrolizumab (MK-3475) in relapsed or refractory classical Hodgkin lymphoma and relapsed/refractory primary mediastinal large B-cell lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Phase 2 | Status: COMPLETED | Results posted: 2025-02-10